Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-07-07

Clinical Trial Update: Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China [Phase 4]

View source ↗

Summary

Phase 4 trial update assessing safety and effectiveness of a delamanid-containing regimen for multidrug-resistant tuberculosis in China.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Delamanid (delamanid)

Snippet

Sponsor: Beijing Chest Hospital | Conditions: Multidrug Resistant Tuberculosis | Phase 4 | Status: UNKNOWN